DK0789021T3 - Hydroxamsyreforbindelser som opioid kappa-receptoragonister - Google Patents

Hydroxamsyreforbindelser som opioid kappa-receptoragonister

Info

Publication number
DK0789021T3
DK0789021T3 DK97200003T DK97200003T DK0789021T3 DK 0789021 T3 DK0789021 T3 DK 0789021T3 DK 97200003 T DK97200003 T DK 97200003T DK 97200003 T DK97200003 T DK 97200003T DK 0789021 T3 DK0789021 T3 DK 0789021T3
Authority
DK
Denmark
Prior art keywords
alkyl
phenyl
optionally substituted
4alkyl
cycloalkyl
Prior art date
Application number
DK97200003T
Other languages
English (en)
Inventor
Fumitaka Ito
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0789021T3 publication Critical patent/DK0789021T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
DK97200003T 1996-02-07 1997-01-07 Hydroxamsyreforbindelser som opioid kappa-receptoragonister DK0789021T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9600099 1996-02-07

Publications (1)

Publication Number Publication Date
DK0789021T3 true DK0789021T3 (da) 2000-11-13

Family

ID=11004404

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97200003T DK0789021T3 (da) 1996-02-07 1997-01-07 Hydroxamsyreforbindelser som opioid kappa-receptoragonister

Country Status (10)

Country Link
US (1) US5837717A (da)
EP (1) EP0789021B1 (da)
JP (1) JP3190588B2 (da)
AT (1) ATE196901T1 (da)
CA (1) CA2196845C (da)
DE (1) DE69703256T2 (da)
DK (1) DK0789021T3 (da)
ES (1) ES2151222T3 (da)
GR (1) GR3034923T3 (da)
MX (1) MX9701042A (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0982297A3 (en) * 1998-08-24 2001-08-01 Pfizer Products Inc. Process for the preparation of hydroxy-pyrrolidinyl hydroxamic acid derivatives being opioid kappa receptor agonists
US7160902B2 (en) 2003-11-14 2007-01-09 Adolor Corporation Amide derivatives and methods of their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618188D0 (en) * 1986-07-25 1986-09-03 Ici Plc Diamine compounds
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
JPH0730061B2 (ja) * 1991-02-07 1995-04-05 ファイザー製薬株式会社 ヒドロキサム酸誘導体および組成物
US5132319A (en) * 1991-03-28 1992-07-21 Merck Frosst Canada, Inc. 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis
US5128364A (en) * 1991-03-28 1992-07-07 Merck Frosst Canada, Inc. Pyrrolo[1,2-a]indole hydroxylamine derivatives as inhibitors of leukotriene biosynthesis
US5234933A (en) * 1991-10-31 1993-08-10 Board Of Governors Of Wayne State University And Vanderbilt University Cyclic hydroxamic acids
IL117440A0 (en) * 1995-03-31 1996-07-23 Pfizer Pyrrolidinyl hydroxamic acid compounds and their production process

Also Published As

Publication number Publication date
ATE196901T1 (de) 2000-10-15
EP0789021B1 (en) 2000-10-11
CA2196845C (en) 2001-08-21
CA2196845A1 (en) 1997-08-08
US5837717A (en) 1998-11-17
DE69703256T2 (de) 2001-02-22
JPH11180950A (ja) 1999-07-06
JP3190588B2 (ja) 2001-07-23
EP0789021A1 (en) 1997-08-13
DE69703256D1 (de) 2000-11-16
ES2151222T3 (es) 2000-12-16
MX9701042A (es) 1998-05-31
GR3034923T3 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
NO20013808L (no) Anti-inflammatoriske indolderivater
HU907660D0 (en) Process for producing tricyclic compounds and pharmaceutical preparatives containing such compounds as active substances
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
WO2002032900A3 (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
ES2102132T3 (es) Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
RU2004125145A (ru) Производные гетероциклических амидов, обладающие ингибиторной активностью в отношении гликогенфосфорилазы
HUP0002272A2 (hu) Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
SE9904508D0 (sv) New compounds
EP0842923A4 (en) PYRROL DERIVATIVES AND MEDICAL PREPARATION.
SK284041B6 (sk) Spirocyklická metaloproteázová inhibítorová zlúčenina a jej použitie
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
RU94044454A (ru) Ингибитор аутоимунных заболеваний
DK0406119T3 (da) Hidtil ukendte peptidderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem
CA2213815A1 (en) Pyrrolidinyl hydroxamic acid compounds and their production process
CA2215659A1 (en) Morphinan hydroxamic acid compounds
HU9800970D0 (en) Process for producing pharmaceutical compositions containing heptapeptide somatostatin derivatives of neurogene- and non-neurogene-antiflogistic and analgesic activity and peptidomimetica
KR950703557A (ko) 약제로서 사용되는 헤테로아릴 화합물(Heteroaryl Compounds Used as Pharmaceuticals)
EA199800155A1 (ru) Новое соединение
DK0789021T3 (da) Hydroxamsyreforbindelser som opioid kappa-receptoragonister
EA200100597A2 (ru) Новые 1,1- и 1,2-дизамещенные циклопропановые соединения, способ их получения и содержащие их фармацевтические композиции
KR880005927A (ko) 카복실산 아미드의 용도
ES2309340T3 (es) Abridor del canal de k activado por calcio de alta conductancia.
AR009374A1 (es) Compuestos novedosos antagonistas de nmda (n-metil-d-aspartato), composicion farmaceutica y usos para fabricar medicamentos.